Head-to-head · WeighScore
Gimme Care vs Hims & Hers
The verdict
Gimme Care takes it — 85/100 to 80/100.
Gimme Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-value both-molecule pricing ($130/$163), verified, and nationwide.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Gimme Care | Hims & Hers |
|---|---|---|
| WeighScore | 85/100 | 80/100 |
| Grade | B | B− |
| Scorecard rank | #9 | #22 |
| Semaglutide | $130/mo | $199/mo |
| Tirzepatide | $163/mo | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #9 · B
Strengths
- $130 sema / $163 tirz
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Not the cheapest tier
- Injection-only
- Monitoring detail limited
Graded #22 · B−
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.